JUUL Crème Brûlée Odds Fall to 9% as No PMTA Filed After JUUL2 Auth

---

Will JUUL Bring Back Flavors in 2026? Here's What the Crème Brûlée Odds Actually Say

JUUL is not bringing back Crème Brûlée anytime soon, according to traders pricing the "What flavors will JUUL relaunch?" market across Kalshi and Polymarket. The FDA authorized the JUUL2 device on August 28, 2026, clearing it for sale with tobacco- and menthol-flavored pods at 1.6% nicotine. JUUL CEO K.C. Crosthwaite publicly stated plans for additional PMTA filings covering a broader flavor portfolio. None of that moved the needle for the dessert category.

Crème Brûlée's implied probability of relaunching by December 31, 2026, has collapsed from 24% to 9% over three days, a 15-percentage-point drop that represents the sharpest move in this market's history. The timing is what makes this noteworthy: the selloff accelerated after the most favorable regulatory development JUUL has received in years. Traders are no longer pricing regulatory risk as the binding constraint. They are pricing corporate inaction.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Crème Brûlée

Consensus YES price across 2 venues

9%average

KalshiBest YES price9¢Polymarket28¢

Mint

Consensus YES price across 1 venues

15%average

KalshiBest YES price16¢

Mango

Consensus YES price across 1 venues

6%average

KalshiBest YES price9¢

Cucumber

Consensus YES price across 1 venues

1%average

KalshiBest YES price9¢

Current new-user offer · Kalshi

Get a $35 trading bonusCode PRED35

New users only. Eligibility restrictions and terms apply.

View current offer

---

What the FDA Actually Authorized for JUUL in 2026, and What It Deliberately Left Out

The August 28 authorization covers a specific hardware platform (JUUL2) and two specific flavor profiles: Virginia Tobacco and Menthol, both at 1.6% nicotine concentration. The FDA cited adult switching rates as high as 49% for menthol as justification, concluding the public health benefit outweighed youth-uptake risk for those particular products.

This is not a blanket flavor approval. Each distinct flavor requires its own Pre-Market Tobacco Product Application, a process that involves toxicological data, behavioral studies on youth appeal, and months of FDA review. Competitor brands like NJOY secured fruit-flavor authorizations in 2026 because they filed proactively and survived the review process. JUUL has not entered that process for Crème Brûlée, Mango, Fruit Medley, or any dessert or fruit variant, based on publicly available FDA docket records.

The distinction matters because search interest around "will JUUL bring back flavors 2026" has spiked since the JUUL2 news. Many readers are conflating device authorization with flavor authorization. The prediction market is not making that mistake. It is pricing the gap between what the FDA permits in theory and what JUUL has actually requested in practice.

---

JUUL Crème Brûlée Relaunch Chances Crashed 15 Points: The Price History

The three-day collapse is counterintuitive on its surface. Positive regulatory news arrived, and the dessert flavor's probability went down. The explanation lies in what traders expected the news to contain versus what it actually delivered. If JUUL was going to announce a broader flavor strategy alongside the JUUL2 authorization, August 28 was the moment. Instead, the company confirmed only tobacco and menthol, with vague forward-looking language about future filings.

The platform spread tells its own story. Kalshi prices Crème Brûlée at just 2%, while Polymarket holds it at 16%. That 14-percentage-point gap is unusually wide and suggests the two trader populations disagree about how much weight to give JUUL's stated intention to file additional PMTAs. Kalshi's U.S.-regulated user base appears to view the corporate timeline as effectively impossible for a 2026 relaunch. Polymarket's international traders are pricing a small but real chance that JUUL surprises.

For context within the same market, Mango sits at 46% implied probability on Polymarket, and Mint at 52%. These flavors already have precedent in JUUL's original lineup and closer analogs in the competitor products the FDA has recently authorized. Crème Brûlée, as a dessert flavor, occupies a different regulatory category. The FDA has shown far more willingness to authorize fruit and menthol profiles than confectionary ones, which face higher scrutiny for youth appeal.

---

The Bull Case for Crème Brûlée: What Would Need to Be True

Dismissing a 9% contract entirely would be a mistake. Four months remain before the December 31 resolution date, and JUUL has explicitly said it plans additional PMTA submissions for a "broader adult-targeted flavor portfolio." If JUUL had a Crème Brûlée PMTA already prepared, perhaps filed quietly or in an expedited review track, the timeline could compress.

There is also a scenario where JUUL announces a reformulated dessert product under a slightly different name that still contains "Crème Brûlée" in the label. The market's resolution criteria specify that the listed flavor name must be "entirely included in the released flavor's name," meaning "Vanilla Crème Brûlée" or "Crème Brûlée Custard" would both qualify. A rebranded product designed to navigate youth-appeal concerns at the FDA could thread this needle.

The strongest version of the bull case rests on competitive pressure. Illicit disposable vapes continue to dominate U.S. market share, and the FDA has signaled receptivity to authorized alternatives that pull users away from unregulated products. If a competitor files for a dessert flavor and receives authorization before Q4, JUUL might accelerate its own timeline. But "might" is doing a lot of work in that sentence, and prediction markets are pricing the verb accordingly.

---

What This Market Tells You About JUUL's Real Strategy

The broader "What flavors will JUUL relaunch?" market is effectively sorting JUUL's product priorities by probability. Mint and Cucumber lead at 52% each on Polymarket, reflecting their lower youth-appeal regulatory burden. Mango follows at 46%. Fruit Medley sits at 28%. Crème Brûlée trails at 9%.

That ordering maps almost perfectly onto the FDA's demonstrated flavor-authorization preferences in 2026. The market is not guessing what JUUL wants to sell. It is ranking what the FDA is likely to clear, filtered through JUUL's own willingness to file. For Crème Brûlée, both filters are working against the contract: the FDA has been least receptive to dessert profiles, and JUUL has shown no public urgency to test that boundary.

With resolution set for December 31 and no PMTA on file, the live JUUL flavor relaunch odds reflect a market that has moved past hope and into calendar math. Even if JUUL filed tomorrow, FDA review timelines for novel flavor applications stretch well beyond four months. The 9% that remains is essentially the probability of a surprise: a pre-positioned filing, an expedited review, or a corporate announcement that nobody outside JUUL's executive suite currently expects.